Societe Adwya (ADWYA)

Tunis
4.65
0.00(0.00%)
  • Volume:
    8,027
  • Bid/Ask:
    4.60/4.65
  • Day's Range:
    4.60 - 4.65

ADWYA Overview

Prev. Close
4.65
Day's Range
4.6 - 4.65
Revenue
97.68M
Open
4.6
52 wk Range
2.62 - 5.2
EPS
0.07
Volume
8,027
Market Cap
100.11M
Dividend (Yield)
0.10 (N/A)
Average Vol. (3m)
23,252
P/E Ratio
62.45
Beta
0.66
1-Year Change
60.9%
Shares Outstanding
21,528,000
Next Earnings Date
-
What is your sentiment on Societe Adwya?
or
Market is currently closed. Voting is open during market hours.

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyStrong SellStrong SellSellStrong Buy
Technical IndicatorsStrong BuyStrong SellStrong SellSellStrong Buy
SummaryStrong BuyStrong SellStrong SellSellStrong Buy

Societe Adwya Company Profile

Societe Adwya Company Profile

Employees
503
Market
Tunisia

Ste Adwya SA is a Tunisia-based company engaged in the provision of generic and licensed pharmaceuticals for human and veterinary use. The Company’s range of products spans several medical areas, including cardiology, dermatology, neuro-psychiatry, metabolism and nutrition, diabetes and urology, among others. It offers drugs traded under the brand name: Novadol, Anxiomyl, Celiprol, Enapril, Glimid, Mesatec, Spirazol and Celopram, among others; drugs manufactured under license agreements with GlaxoSmithkline, Solvay, Sanofi-Aventis, Abbot, and Astra Zeneca, among others, and drugs prepared for third party laboratories. The Company operates two production sites: Alpha, which manufactures the non-penicillin products, and Beta, which specializes in the production of antibiotics. The new branch of activity launched by the Company is the natural therapy range, API-AR and multivitamins range, Advita multivitamins. In February 2014, it established a subsidiary Adwya Promotion Cote d'Ivoire.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.